We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
PacBio posted strong Q4 results with revenue and earnings beating expectations across segments.
PACB is gaining from HiFi sequencing tech and growing adoption of Revio and Vega systems.
PacBio faces longer sales cycles as funding constraints delay high-cost system purchases.
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong fourth-quarter results, is expected to contribute further. However, concerns about long purchasing cycles persist.
In the year-to-date period, this Zacks Rank #1 (Strong Buy) company’s shares have lost 29.4% compared with the 13.4% decline of the industry. The S&P 500 Composite has declined 4.9% in the said time frame.
The renowned global provider of sequencing systems has a market capitalization of $380.5 million. The company projects 11.1% growth for 2027 and expects to maintain its strong performance going forward. PacBio’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average surprise of 27.7%.
Image Source: Zacks Investment Research
Factors Favoring PACB’s Growth
Sequencing Technologies Strengthen Market Leadership: PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology. This technology enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes and epigenetic modifications.
Per a report by Data Bridge Market Research, the global SMRT market size was valued at $2.88 billion in 2024 and is projected to reach $4.36 billion by 2032, at a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating Sequencing by Binding chemistry with the launch of its Onso system in 2022, a short-read platform delivering ≥90% of bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By providing both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while driving down costs and enhancing variant detection.
Robust Product Portfolio Driving Growth: PACB closed the fourth quarter of 2025 with clear momentum across its product portfolio, led by the Revio System and Vega System, alongside a rapidly scaling consumables business. The company shipped 21 Revio and 42 Vega systems during the quarter, taking cumulative placements to 331 and 147, respectively. This reflects steady adoption trends even amid a constrained academic funding environment, highlighting the resilience of demand and the growing relevance of PacBio’s long-read sequencing platforms.
Importantly, underlying trends point to strengthening customer engagement. Revio placements rebounded meaningfully in the fourth quarter, with improving utilization and about 20% of 2025 orders coming from multisystem customers—an encouraging sign of scaling usage and future consumables growth. Meanwhile, Vega continues to serve as a powerful entry point, with roughly 65% of placements coming from new-to-PacBio customers. This indicates the company is not only deepening relationships with existing users but also successfully expanding its installed base, setting up a durable long-term growth engine.
Strong Q4 Results: PACB exited the fourth quarter of 2025 on a strong note, delivering results that surpassed both earnings and revenue expectations. Growth across all business segments was particularly encouraging, signaling healthy underlying demand. Margins also moved in the right direction, with adjusted gross margin expansion and a narrower operating loss reflecting improved cost discipline and operating leverage—both positive indicators for investors tracking the company’s path toward profitability.
Strategically, PacBio continued to double down on its long-read sequencing leadership. The company joined the iHope Program as its first long-read sequencing partner, while collaborations with n-Lorem Foundation and EspeRare Foundation reinforced its push into precision medicine. At the same time, HiFi sequencing gained further validation in clinical research, including use in investigating sudden unexplained death in children. On the innovation front, PacBio expanded into multiomics with the launch of CiFi—developed alongside the University of California, Davis—enabling chromosome-scale genome assembly from a single SMRT Cell, further strengthening its technology moat.
A Factor That May Offset the Gains for PACB
Longer Purchasing Cycles: PacBio continues to face prolonged sales cycles for its high-cost Revio sequencing system, as customers navigate ongoing funding constraints and capital spending caution. Management highlighted that the academic and government funding environment remains challenging, particularly in the Americas, where uncertainty around grant timing and budget visibility continues to delay purchasing decisions. While Revio placements showed improvement sequentially in the fourth quarter, full-year instrument sales were still impacted by these pressures, reflecting muted capital equipment demand.
The company expects these challenges to persist into 2026, with management explicitly stating that it does not anticipate a meaningful recovery in academic funding or capital spending in the near term.
Estimate Trend
PacBio has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed by 3 cents to 54 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $175.4 million, indicating a 9.6% increase from the year-ago reported numbers.
Other Key Picks
Currently, WST carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted EPS of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add PacBio Stock to Your Portfolio Now
Key Takeaways
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong fourth-quarter results, is expected to contribute further. However, concerns about long purchasing cycles persist.
In the year-to-date period, this Zacks Rank #1 (Strong Buy) company’s shares have lost 29.4% compared with the 13.4% decline of the industry. The S&P 500 Composite has declined 4.9% in the said time frame.
The renowned global provider of sequencing systems has a market capitalization of $380.5 million. The company projects 11.1% growth for 2027 and expects to maintain its strong performance going forward. PacBio’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average surprise of 27.7%.
Image Source: Zacks Investment Research
Factors Favoring PACB’s Growth
Sequencing Technologies Strengthen Market Leadership: PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology. This technology enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes and epigenetic modifications.
Per a report by Data Bridge Market Research, the global SMRT market size was valued at $2.88 billion in 2024 and is projected to reach $4.36 billion by 2032, at a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating Sequencing by Binding chemistry with the launch of its Onso system in 2022, a short-read platform delivering ≥90% of bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By providing both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while driving down costs and enhancing variant detection.
Robust Product Portfolio Driving Growth: PACB closed the fourth quarter of 2025 with clear momentum across its product portfolio, led by the Revio System and Vega System, alongside a rapidly scaling consumables business. The company shipped 21 Revio and 42 Vega systems during the quarter, taking cumulative placements to 331 and 147, respectively. This reflects steady adoption trends even amid a constrained academic funding environment, highlighting the resilience of demand and the growing relevance of PacBio’s long-read sequencing platforms.
Importantly, underlying trends point to strengthening customer engagement. Revio placements rebounded meaningfully in the fourth quarter, with improving utilization and about 20% of 2025 orders coming from multisystem customers—an encouraging sign of scaling usage and future consumables growth. Meanwhile, Vega continues to serve as a powerful entry point, with roughly 65% of placements coming from new-to-PacBio customers. This indicates the company is not only deepening relationships with existing users but also successfully expanding its installed base, setting up a durable long-term growth engine.
Strong Q4 Results: PACB exited the fourth quarter of 2025 on a strong note, delivering results that surpassed both earnings and revenue expectations. Growth across all business segments was particularly encouraging, signaling healthy underlying demand. Margins also moved in the right direction, with adjusted gross margin expansion and a narrower operating loss reflecting improved cost discipline and operating leverage—both positive indicators for investors tracking the company’s path toward profitability.
Strategically, PacBio continued to double down on its long-read sequencing leadership. The company joined the iHope Program as its first long-read sequencing partner, while collaborations with n-Lorem Foundation and EspeRare Foundation reinforced its push into precision medicine. At the same time, HiFi sequencing gained further validation in clinical research, including use in investigating sudden unexplained death in children. On the innovation front, PacBio expanded into multiomics with the launch of CiFi—developed alongside the University of California, Davis—enabling chromosome-scale genome assembly from a single SMRT Cell, further strengthening its technology moat.
A Factor That May Offset the Gains for PACB
Longer Purchasing Cycles: PacBio continues to face prolonged sales cycles for its high-cost Revio sequencing system, as customers navigate ongoing funding constraints and capital spending caution. Management highlighted that the academic and government funding environment remains challenging, particularly in the Americas, where uncertainty around grant timing and budget visibility continues to delay purchasing decisions. While Revio placements showed improvement sequentially in the fourth quarter, full-year instrument sales were still impacted by these pressures, reflecting muted capital equipment demand.
The company expects these challenges to persist into 2026, with management explicitly stating that it does not anticipate a meaningful recovery in academic funding or capital spending in the near term.
Estimate Trend
PacBio has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed by 3 cents to 54 cents.
The Zacks Consensus Estimate for 2026 revenues is pegged at $175.4 million, indicating a 9.6% increase from the year-ago reported numbers.
Other Key Picks
Currently, WST carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted EPS of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.